BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29719377)

  • 21. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
    Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MEK inhibition overcomes everolimus resistance in gastric cancer.
    Liu H; Yao Y; Zhang J; Li J
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1079-1087. PubMed ID: 32444897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
    Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.
    Chauhan A; Ojha R; Semwal DK; Mishra SP; Semwal RB
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1545-1554. PubMed ID: 28270077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
    Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
    Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future perspectives for mTOR inhibitors in renal cell cancer treatment.
    Czarnecka AM; Kornakiewicz A; Lian F; Szczylik C
    Future Oncol; 2015; 11(5):801-17. PubMed ID: 25757683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.
    Liu L; Wang Q; Mao J; Qin T; Sun Y; Yang J; Han Y; Li L; Li Q
    Chem Biol Interact; 2018 Dec; 296():145-153. PubMed ID: 30273566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
    Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
    Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phanginin R Induces Cytoprotective Autophagy via JNK/c-Jun Signaling Pathway in Non-Small Cell Lung Cancer A549 Cells.
    Zhang LL; Bao H; Xu YL; Jiang XM; Li W; Zou L; Lin LG; Lu JJ
    Anticancer Agents Med Chem; 2020; 20(8):982-988. PubMed ID: 32286950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
    Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
    Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy.
    Zhang W; Yang C; Zou L; Zang Y; Hu J; Hu Y; Xu C; Liu R; Wang H; Xiong Z
    J Appl Genet; 2024 Feb; 65(1):103-112. PubMed ID: 37932653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of ERK and activation of p38 are involved in diallyl disulfide induced apoptosis of leukemia HL-60 cells.
    Tan H; Ling H; He J; Yi L; Zhou J; Lin M; Su Q
    Arch Pharm Res; 2008 Jun; 31(6):786-93. PubMed ID: 18563362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.